Chief Medical Officer & Senior Principal Investigator
William W. O'Neill, MD, FACC
Senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background.
Role at Amavita Research
Chief Medical Officer & Senior Principal Investigator
Biography
Dr. William W. O'Neill is a senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background. He and has spent more than four decades advancing minimally invasive cardiovascular care.
Dr. O'Neill currently serves as Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit and as Chief Medical Officer at Amavita Research. He has served as National Principal Investigator (chair) of the PROTECT II trial, Steering Committee member for PROTECT IV, and Principal Investigator at Henry Ford for the PARTNER trial, and is the founder of the National Cardiogenic Shock Initiative — a multi-center quality improvement program that established the modern standard of care for AMI cardiogenic shock.
He has authored or co-authored more than 400 peer-reviewed publications and has trained generations of interventional cardiologists. At Amavita Research he provides scientific oversight, protocol design input, and senior PI leadership across the active cardiovascular trial portfolio.
Specialties & Focus Areas
- Structural heart disease
- TAVR & transcatheter valve therapy
- High-risk PCI & cardiogenic shock
- Pivotal device trial leadership
Therapeutic areas
Education & Credentials
- MD — Wayne State University School of Medicine
- Internal Medicine Residency — University of Michigan
- Cardiovascular Disease Fellowship — University of Michigan
- FACC — American College of Cardiology
Notable Publications
- Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients (PARTNER 3) — Mack MJ, Leon MB, Thourani VH, … O'Neill WW, et al. N Engl J Med. 2019;380(18):1695–1705. link →
- A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 vs Intra-Aortic Balloon Pump in Patients Undergoing High-Risk PCI (PROTECT II) — O'Neill WW, Kleiman NS, Moses J, et al. Circulation. 2012;126(14):1717–1727. link →
- The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry — O'Neill WW, Schreiber T, Wohns DH, et al. J Interv Cardiol. 2014;27(1):1–11.
- National Cardiogenic Shock Initiative: A Standardized Treatment Protocol for AMI Cardiogenic Shock — Basir MB, Kapur NK, Patel K, … O'Neill WW. Catheter Cardiovasc Interv. 2019;93(7):1173–1183.
Notable Trials
- PARTNER (Principal Investigator at Henry Ford)
- PROTECT II (National Principal Investigator and chair)
- PROTECT IV (Steering Committee member)
- National Cardiogenic Shock Initiative (Founder)
Affiliations
- Amavita Research Services LLC
- amavita Heart and Vascular Health®
- Center for Structural Heart Disease, Henry Ford Hospital